PerformanceResearch Phase

Melanotan II

Subcutaneous injection

Overview

A synthetic cyclic analog of alpha-melanocyte stimulating hormone (alpha-MSH) that non-selectively activates melanocortin receptors MC1R through MC5R. Melanotan II stimulates melanogenesis for skin tanning via MC1R, modulates sexual arousal through MC3R/MC4R in the hypothalamus, and reduces appetite through central MC4R activation.

Mechanism of Action

It is not FDA-approved and carries significant safety concerns..

Research Summary & Key Findings

Research demonstrated effective UV-independent melanogenesis and photoprotective effects. Also showed erectogenic effects in clinical studies, leading to development of PT-141. Safety concerns include nausea, facial flushing, potential for melanocyte dysregulation, and unregulated product quality. Not approved by any major regulatory agency.

Clinical Status

Research Phase

Melanotan II is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Subcutaneous injection

Related Peptides in Performance

Find a Provider

Find a verified provider who offers Melanotan II therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Melanotan II.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.